Overview
CAMRIS provides military medicine, clinical and life sciences research and development services to U.S. federal government clients, drawing on experience in more than 110 countries. Its offerings span health and wellness programs for service members, clinical trials, and life sciences research, delivered through evidence-based methods and proven systems. The company emphasizes a customer-centered, cost-conscious approach and a lean, nimble structure that allows customized, end-to-end solutions rather than one-size-fits-all products, enabling faster adaptation to changing requirements. By focusing on smarter, faster, and more flexible ways to meet government needs, CAMRIS aims to improve overall health outcomes for service members while delivering value to its government customers.
Work here?Claim your company
Simplify's take
What believers are saying
- CAMRIS highlighted Artemis II support on July 5, 2026, strengthening credibility with defense health buyers.
- The August 2026 World Vaccine Congress appearance reinforces its bioproduction and vaccine-services positioning.
- GSA shows OASIS+ Unrestricted options through December 16, 2029, supporting longer sales runway.
What critics are saying
- Houedenou v. CAMRIS and Rashad v. Camris International in 2026 spotlight employment exposure.
- Federal contract dependence concentrates revenue risk; one recompete loss can hit staffing and margins fast.
- If NIH, DHA, or NASA vehicle access slips, CAMRIS loses its core procurement advantage.
What makes CAMRIS unique
- CAMRIS sells federal-life-sciences execution, not generic staffing, across DoD, NIH, and NASA.
- Its OASIS+ award and OMNIBUS IV access widen bidding reach through 2029.
- The Artemis II NHRC support shows rare ability to operate inside mission-critical lab workflows.
Help us improve and share your feedback! Did you find this helpful?